Physician profile
Ryan V Marshall
NPI 1447614813
$9,248.41
in general payments reported to CMS, 2019-2025
24 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what 87% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.70 · 2020: $44.20 · 2021: $12.99 · 2022: $1,957 · 2023: $2,396 · 2024: $3,193 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,558 · Travel and Lodging: $2,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,558.06 |
| Travel and Lodging | $2,630.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $2,175.95 | 2022-2025 | |
| Smith+Nephew, INC. | $2,170.96 | 2024 | Coblation, Tula, Halo |
| Inspire Medical Systems, INC. | $1,831.29 | 2022-2025 | Inspire |
| Glaxosmithkline, LLC. | $725.06 | 2022-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $346.86 | 2022-2025 | Dupixent |
| Karl Storz Endoscopy-America | $287.18 | 2022-2025 | Tele Pack |
| Medtronic, INC. | $240.23 | 2022-2024 | Propel |
| Astrazeneca Pharmaceuticals LP | $229.16 | 2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $225.20 | 2022-2025 | |
| Integra Lifesciences Corporation | $188.20 | 2024-2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Neurent Medical Limited | $131.92 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Aroa Biosurgery Incorporated | $130.86 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $123.11 | 2025 | Neffy |
| Intersect Ent, INC. | $116.50 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $56.25 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $45.70 | 2019 | |
| Genentech USA, INC. | $43.22 | 2025 | Xolair |
| Kaleo, INC. | $37.32 | 2022 | |
| Amgen INC. | $33.75 | 2025 | Tezspire |
| Acclarent, INC | $31.40 | 2023 | Trudi Nav Cable |
| Takeda Pharmaceuticals U.S.A., INC. | $28.29 | 2025 | Cuvitru |
| Kci USA, INC. | $18.80 | 2023 | Promogran Prisma, Activ.A.C. |
| Siemens Medical Solutions USA, INC. | $17.49 | 2025 | Immulite 1000 Immunoassay System |
| Hikma Pharmaceuticals USA | $13.71 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.